The effect of aging on intact PTH and bone density in women: J Am Geriatr Soc 1992; 40: 1135-8Flicker L, Lichtenstein M, Colman P, et al. The effect of aging on intact PTH and bone density in women. JAm Geriatr Soc. 1992;40:1135-1138....
May2011toAugust2012,wereselected.Theserumlevelsof25(OH)DandPTHweredetected.Andthecorrelation amongseium25(OH)Dlevels,PTHlevels,boneconversionmetrics,andregionalbonemineraldensity(BMD)was analyzed.Results Serum25(OH)Dlevelswashigherthan30n【 mLin46.7%youngmen,lowerthan30ng/mLin 53.3% ...
Comparison of PTH secretion and bone metabolism in adult growth hormone deficient patients with normal and reduced bone mineral densityBACKGROUND: AGHD is associated with reduced BMD. GHR results in improvement in BMD, however, some patients remain osteopaenic despite all appropri...
Tibia and femur measurements included bone morphometry, bone turnover markers, determination of bone mineral density (BMD) and bone mineral content (BMC) by dual energy X-ray absorptiometry (DXA) and bone strength by three-point bending test. The effect of sugar-sweetened beverage consumption on ...
因此应重视维生素D的补充及生活方式的改变.%Objective To investigate the serum 25-hydroxyvitamin D (250HD), parathyroid hormone (PTH), and bone mineral density ( BMD) of healthy people and to analyze the 250HD status in winter and the relationship between 250HD and BMD in She region in Fu...
展开更多 Objective To investigate the relationship among 25 (OH) D, parathyroid hormone (PTH) levels and regional bone mineral density in young men in Guangzhou. Methods Sixty young men, aging from 18 to 44 years old, who came to the outpatient department in the General Hospital...MORE ...
近年来,慢性肾脏疾病(CKD)发病率的升高,进入肾脏替代治疗的患者明显增多,随之出现一系列的并发症及合并症,肾性骨病(ROD)就是一种明显影响患者生存质量的长期并发症,其发病率几乎达到100%[1]2006年KDIOG会议提出了”慢性肾脏病-矿物质和骨代谢病变(chronic kidney disease-mineral and bone disorder,CKD-MBD)”的概...
However, while the correlation between lower PTH and osteocalcin was seen in diabetics of both sexes, only the diabetic women in the study were seen at elevated fracture risk independent of bone mineral density (J. Clin. Endocrinol. Metab. 2012 Feb. 15 [doi:10.1210/jc.2011-2537]). The ...
(1-37) (human) is supposed to be the native bioactive fragment of pTH (1-84) (human) in circulation. Furthermore it was shown that pulsatile but not continuous administration of pTH (1-37) (human) increased growth, bone calcium content, and bone mineral density in uremic animals.Soluble...
Human rPTH (1-34) has been produced by recombinant technologies, is now approved, and will soon be available for the treatment of osteoporosis. It is given subcutaneously, 25 μg/day cyclically for 12 to 18 months, to increase bone density in individuals with a history of fractures, severe...